# Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies

> **NCT05598788** · — · UNKNOWN · sponsor: **Rennes University Hospital** · enrollment: 360 (estimated)

## Conditions studied

- Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

## Interventions

- **OTHER:** Measurement of drug concentrations

## Key facts

- **NCT ID:** NCT05598788
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-03
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598788, "Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05598788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*